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doi:10.1Objective: Obliterative bronchiolitis is the predominant histopathologic finding in patients with chronic
rejection after lung transplant. This fibroproliferative transformation within small airways of lung allograft is
poorly understood; however, studies suggest epithelial–mesenchymal transition plays a role. Transplant immu-
nosuppressive therapy has been shown to cause epithelial–mesenchymal transition in renal tubular epithelial
cells, with subsequent fibrosis. This study explored whether immunosuppressive therapy contributes to
epithelial–mesenchymal transition in airway epithelial cells.
Methods: Bronchial epithelial cell line RL-65 was treated 3 to 5 days with several immunosuppressive agents,
including cyclosporine (INN ciclosporin), tacrolimus, azathioprine, mycophenolic acid, sirolimus, prednisone,
and transforming growth factor b1 as control. We then analyzed cells for presence of mesenchymal morphology
and protein markers.
Results: Treatment with cyclosporine, azathioprine, mycophenolate, and sirolimus resulted in elongated and ir-
regular cell shape, and all but azathioprine showed loss of cell–cell adhesions relative to vehicle-treated cells.
Expressions of extracellular matrix proteins, fibronectin and collagen, along with mesenchymal marker, vimen-
tin, were significantly upregulated. Immunofluorescence showed loss of E-cadherin at cell membranes and cy-
toskeletal rearrangements typical of epithelial–mesenchymal transition. These immunosuppressive agents also
increased transforming growth factor produced by cells; however, tacrolimus- and prednisone-treated cells
maintained epithelial morphology, baseline levels of matrix protein expression, and transforming growth factor
production levels.
Conclusions: Overall, we found that certain immunosuppressive agents may contribute to partial epithelial–
mesenchymal transition in bronchial epithelial cells, specifically increasing production of excessive extracellu-
lar matrix proteins. This may provide novel insights into the pathogenesis of obliterative bronchiolitis after lung
transplant. (J Thorac Cardiovasc Surg 2011;141:523-30)T
XLung transplant is the preferred management strategy for
selected patients with progressive end-stage lung disease.
Improvements in donor and recipient selection, surgical
techniques, and immunosuppression have led to substantial
gains in short-term survival, with current 1-year survival ap-
proaching 85%; however, long-term outcomes after lung
transplant remain much lower than desired, with 5-year sur-
vival approximately 50% according to Organ Procurement
and Transplant Network data as of January 1, 2010 (http://
optn.transplant.hrsa.gov). The primary factor limiting long-
term survival after transplant is chronic rejection, the histo-
logic manifestation of which is obliterative bronchiolitise Center for Thoracic Disease, Heart and Lung Institute, St Joseph’s Hospital
edical Center, Phoenix, Ariz.
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The Journal of Thoracic and Ca(OB).1 OB is characterized by remodeling and fibrotic ob-
struction of the smaller airways.2 This is essentially an irre-
versible process that leads to progressive airflow limitation
and allograft dysfunction, resulting in substantial patient
morbidity and mortality.
The pathogenesis of OB remains poorly understood;
however, clinical observations and in vitro investigations
have suggested that OB may represent a pathologic healing
response from cellular and antibody-mediated alloimmune
injury, as well as virally mediated injury to the airway epi-
thelium.3,4 It is increasingly recognized that clinically silent
injuries also occur that may lead to airway epithelial injury
and subsequent chronic rejection. During this healing
response, fibroblasts will contract, causing wound closure,
and lay down extracellular matrix (ECM) for new
epithelium to grow along. Improperly regulated ECM
deposition is thought to result in excess nonfunctional
fibrous tissue, such as that seen in idiopathic pulmonary
fibrosis. The fibrous buildup within the walls of small
airways in OB may result from a similar process.
The origin of the fibroblasts responsible for the airway
wall fibrosis and luminal occlusion is unknown. Potential
sources include in situ proliferation of resident fibroblastsrdiovascular Surgery c Volume 141, Number 2 523
Abbreviations and Acronyms
AQP5 ¼ aquaporin 5
ECAD ¼ E-cadherin
ECM ¼ extracellular matrix
EMT ¼ epithelial–mesenchymal transition
OB ¼ obliterative bronchiolitis
TGF-b1 ¼ transforming growth factor b1
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Xand recruitment of circulating mesenchymal stem cells.5,6
There has also been increasing interest in the ability of
epithelial cells to undergo epithelial–mesenchymal
transition (EMT) mediated by transforming growth factor
b1 (TGF-b1). EMT has been demonstrated in many
organ epithelial cell types and disease processes. In the
lung, it has primarily been described in alveolar epithelial
cells and is thought to be a primary contributor to the
pathogenesis of pulmonary fibrosis.7 More recently, others
have demonstrated that bronchial epithelial cells also have
the capacity to undergo TGF-b1–mediated EMT.8 EMT
may therefore play a role in the development of OB by re-
sulting in the transition of airway epithelium to fibroblast-
like cells that deposit excess ECM, constricting the airway.
TGF-b1 has been implicated as themain cytokine trigger-
ing EMT. Increased TGF-b1 is associated with both clinical
and experimental OB.9,10 In addition, immunosuppressive
agents such as cyclosporine (INN ciclosporin) induce
renal tubular interstitial fibrosis.11 Furthermore, it has
been shown that the fibrogenic nature of cyclosporine is sec-
ondary to proximal tubular renal epithelial cell EMT that is
associated with upregulation of TGF-b1 secretion. We
therefore hypothesized that immunosuppressive drugs also
contribute to the fibrosis of the airways by triggering EMT
in bronchial airway epithelial cells.
In this study, we sought to characterize further the capac-
ity of bronchial epithelial cells to undergo EMT and to de-
termine whether common immunosuppressive drugs play
a role in the induction of EMT in bronchial epithelial cells.
We examined total cellular concentrations of epithelial and
mesenchymal markers with immunoblot and localization
changes of markers with immunofluorescence. We quanti-
fied the productions of the ECM proteins excreted from
the cells in the presence of each drug. Finally, we assessed
whether the cause of increased ECM protein production was
an increase in TGF-b1 production by the epithelial cells
themselves.
MATERIALS AND METHODS
Cell Culture
RL-65 cells, a spontaneously immortalized rat bronchial epithelial cell
line,12were purchased fromATCC (Manassas,Va) and cultured inDulbecco
modified Eagle medium and F12-Hamm medium supplemented with
2.5-mmol/L glutamine, 5-mmol/L insulin, 10-mg transferrin, 2.5-mL524 The Journal of Thoracic and Cardiovascular Surgbovine pituitary extract, nonessential amino acids, 100-U/mL penicillin,
and 100-mg/mL streptomycin. Cells were treated with vehicle (5 mL dime-
thylsulfoxide), 2.5-ng/mL recombinant human TGF-b1 (R&D Systems,
Inc,Minneapolis,Minn), or immunosuppressive drugs. Immunosuppressive
drugs cyclosporine, tacrolimus, azathioprine, mycophenolic acid, and pred-
nisone were purchased from Sigma (Sigma-Aldrich Co, St Louis, Mo) and
sirolimus was purchased from Calbiochem (EMD Chemicals Inc, Gibbs-
town, NJ). Doses for each drug were as follows: cyclosporine 1 mmol/L,
tacrolimus 5 mmol/L, azathioprine 500 nmol/L, mycophenolic acid
500 nmol/L, sirolimus 20 nmol/L, and prednisone 5 mmol/L. Drug doses
were determined from published patient and pharmacokinetic data and
adjusted for tolerance by the cell line.13,14 Because bioavailability of
immunosuppressive compounds varies highly among patients, we used
the highest dose within therapeutic range before a loss of cell viability
was seen. Tacrolimus, for example, was assayed at a higher than normal
dose because of a high tolerance for the drug by the cells. Cells were
redosed every 24 hours and maintained at 37C and 5% carbon dioxide
for 3 to 5 days. Cell viability and metabolic activity were confirmed with
a Resazurin fluorescence conversion assay (Promega Corporation,
Madison,Wis). No significant loss of cell viability was seen at chosen doses.
Immunoblotting
After treatment, cell cultures were lysed with sodium dodecylsulfate
buffer and sonicated. Protein concentrations were estimated with a deter-
gent-compatible assay kit from Bio-Rad (Bio-Rad Laboratories, Hercules,
Calif). Samples were run on a 10% acrylamide gel, transferred to nitrocel-
lulose membrane, blocked, and incubated overnight at 4C with appropri-
ate primary antibody. Primary antibodies included antifibronectin antibody
(Sigma), anti–aquaporin 5 (AQP5) antibody (Santa Cruz Biotechnology,
Inc, Santa Cruz, Calif), anti–E-cadherin (ECAD) antibody (BDBioscience,
BD, Franklin Lakes, NJ), antivimentin antibody (Sigma), and anti–B-actin
antibody (Sigma). Membranes were washed and incubated with horserad-
ish peroxidase–conjugated secondary antibodies (Cell Signaling Technol-
ogy, Inc, Danvers, Mass) for 2 hours at room temperature. Membranes
were developed and imaged on a Kodak Image Station (Eastman Kodak
Company, Rochester, NY).
Immunofluorescence
Cells were grown on coverslips and treated as stated previously, then
fixed for 30 minutes with 4% paraformaldehyde. Coverslips were reper-
meabilized with methanol or 0.2% Triton-X 100 (Dow Chemical Com-
pany, Midland, Mich), blocked, and incubated overnight at 4C with
primary antibody. Alexaflour 488 (Life Technologies, Carlsbad, Calif) sec-
ondary antibody and conjugated phalloidin antibody incubation was car-
ried out at room temperature for 2 hours. Coverslips were then mounted
on slides with Vectashield (Vector Laboratories, Inc, Burlingame, Calif)
with 40,6-diamidino-2-phenylindole and imaged. Brightfield images of
cell cultures were taken at equivalent time points.
Soluble Collagen Assay
Media samples from cell cultures were harvested after 5 days of treat-
ment and a full 24 hours after last medium change. Samples were incubated
with binding dye, Sirius red (Sircol; Biocolor Ltd, Carrickfergus, UK) as-
say for soluble collagens. Dye-bound samples were pelleted, resuspended
in buffer, then plated on a 96-well plate. Absorbance was measured at 535
nm. Measurements were normalized to total protein concentration taken
from the samples at the time of media harvest.
TGF-b1 Enzyme-Linked Immunosorbent Assay
Medium samples from cell cultures were harvested after 2 full days of
pretreatment with immunosuppressive drugs, then allowing for another full
24 hours of TGF-b1 secretion with fresh media. Samples were treated
to measure content of total excreted cytokine, including active andery c February 2011
Felton et al Cardiothoracic Transplantationlatent TGF-b1. Samples were assayed on a TGF-b1 enzyme-linked immu-
nosorbent assay (R&D Systems) plate and read at 450 nm. Measurements
were normalized to total cellular protein concentration of lysates taken at
the time of medium harvest.
Anti–TGF-b1 Rescue
To confirm that the effects of the immunosuppressive drugs on the cells
were due to induced TGF-b1 production, we pretreated the cells for 30
minutes with anti–TGF-b1 (5 ng/mL) before treating cells with TGF-b1
or immunosuppressive drugs. This pretreatment was repeated for every me-
dium change and redosing for 3 days. Cells were assessed morphologically,
and lysates were analyzed by immunoblot for fibronectin production.
Statistical Analysis
Experiments were performed in triplicate. Quantitative analyses were
expressed as mean  SEM.RESULTS
Cell Morphology
Vehicle-treated cells exhibited a typical epithelial mor-
phology (Figure 1), including a consistent round shape
and a tightly junctioned monolayer. Cells treated with
TGF-b1 begin to detach from each other, losing cell–cell ad-
hesion, and to elongate and flatten out significantly. Cyclo-
sporine-, mycophenolic acid–, and sirolimus-treated cells
mimicked the morphology changes observed with TGF-b1
treatment, including loss of cell adhesions and change in
cell shape. Azathioprine-treated cells; however, showed ir-
regularity in cell shape without the loss of cell–cell contact
seen in TGF-b1–treated cells. Cells treated with tacrolimus
and prednisone exhibited no change in morphology and
were nearly indistinguishable from untreated control cells.FIGURE 1. Morphology of immunosuppressive drug treated bronchial
epithelium. RL-65 cells normally exhibit consistent round shape and tightly
junctioned cobblestone monolayer. In presence of transforming growth factor
b1 (TGF), however, cells began to flatten, elongate, and lose cell–cell adhesions,
adoptingmorefibroblastlikemorphology.Similar changeswere seen in response
to cyclosporine (CSA),mycophenolic acid (MMF), and sirolimus (RAPA).Aza-
thioprine (AZA) elicited elongated and inconsistent cell shape with noticeably
less loss of cell–cell adhesions. Cells treated with tacrolimus (TAC) and predni-
sone (PRED) were indistinguishable from those treated with vehicle (VEH).
T
XExpressions of Epithelial and Mesenchymal Markers
Expressions of the epithelial and mesenchymal markers
were assessed by immunoblot (Figure 2). The epithelial
markers AQP5 and ECAD were highly expressed in
vehicle-treated cells. In the presence of TGF-b1, the cells
lost their AQP5 expression, and with each immunosuppres-
sive drug treatment, expression of AQP5 nearly disap-
peared. Overall expression of ECAD, a tight junction
protein, was not reduced in the presence of TGF-b1 or im-
munosuppressive drugs.
The mesenchymal markers fibronectin and vimentin are
normally expressed at low or undetectable levels. The ECM
protein fibronectin showed a marked increase with TGF-b1
treatment, as well as with cyclosporine, mycophenolic acid,
and sirolimus treatments. A slight increase was also noted
with azathioprine treatment. Vimentin expression was in-
creased in response to both TGF-b1 and immunosuppressive
drug treatments. Notably, however, this was a much less pro-
nounced increase than we saw in preliminary experiments
with alveolar type II cells. Tacrolimus- and prednisone-
treated cells were comparable to vehicle-treated cells in levels
of mesenchymal marker expression.The Journal of Thoracic and Cardiovascular Surgery c Volume 141, Number 2 525
FIGURE 2. Immunoblot analysis of epithelial and mesenchymal markers.
Cell lysates were analyzed for epithelial markers aquaporin 5 (AQP5) and
E-cadherin. Aquaporin 5 expression ceased in presence of transforming
growth factor b1 (TGF) and in cells treated with cyclosporine (CSA). Cells
treated with tacrolimus (TAC), azathioprine (AZA), mycophenolic acid
(MMF), and sirolimus (RAPA) all demonstrated significant loss of aquaporin
5 expression. Expression of E-cadherin remained consistent with control
cells for transforming growth factor b1 and all drug treatments. Expression
of mesenchymal marker and ECM protein fibronectin was greatly increased
in response to transforming growth factor b1. Cyclosporine and mycophe-
nolic acid elicited increased expression levels of fibronectin, similar to
that of transforming growth factor b1. Azathioprine-treated cells showed
slight increase in both fibronectin and vimentin. Prednisone-treated cells
exhibited similar expression profile to that of vehicle-treated cells.
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XLocalization Changes of EMT Markers
Immunofluorescence was used to assess changes in local-
ization of epithelial and mesenchymal markers (Figure 3).
Phalloidin staining was used to assess actin cytoskeletal
changes. Vehicle-treated cells maintained a honeycomb
cortical actin ring at the membrane of each cell, whereas
TGF-b1–treated cells lost this ring and began displayingFIGURE 3. Immunofluorescence localization of epithelial and mesenchymal
cortical actin ring throughout cell monolayer. Treatment with transforming gro
stress fibers. Cyclosporine (CSA), mycophenolic acid (MMF), and sirolimus (
growth factor b1. Azathioprine (AZA)–treated cells maintained their cortical ac
regular compared with VEH-treated cells. Transforming growth factor b1, cycl
herin (ECAD) localization at cell membrane relative to vehicle-treated cells, whe
cortical actin ring and membrane-associated E-cadherin expression. Transform
did cyclosporine, mycophenolic acid, and sirolimus treatments. AZA-treated c
taining ECAD expression. Tacrolimus- and prednisone-dosed cells maintained
526 The Journal of Thoracic and Cardiovascular Surgstress fibers throughout the cell. Cyclosporine-, mycophe-
nolic acid–, and sirolimus-treated cells displayed this
altered actin organization with loss of actin ring and mild
formation of stress fibers, resembling TGF-b1–treated cells,
whereas cells treated with tacrolimus, azathioprine, and
prednisone generally maintained cytoskeletal structure
and integrity of the actin ring.
ECAD localization in TGF-b1–treated cells was dis-
tinctly different from that in vehicle-treated cells, even
though no decrease in overall expression level was seen by
immunoblot, as stated previously. TGF-b1–treated cells
showed a distinct loss of ECAD at the cell membrane.
Cyclosporine-, mycophenolic acid–, and sirolimus-treated
cells also lost ECADat the cellmembrane. Tacrolimus-, aza-
thioprine-, and prednisone-treated cells maintained cell–cell
junctions and localization of ECAD at the cell membrane.
TGF-b1–treated cells made large deposits of fibronectin
relative to vehicle-treated cells. Cyclosporine, mycophe-
nolic acid–, and sirolimus-treated cells also exhibited fibro-
nectin deposition similar to that of TGF-b1–treated cells,
whereas tacrolimus-, azathioprine-, and prednisone-
treated cells did not exhibit a large increase in fibronectin
deposition. Azathioprine-treated cells, however, showed
significant nuclear blebbing (image not shown), typically
associated with preapoptotic cells, relative to mycophenolic
acid treatment.
Collagen Production
Medium from cell cultures was harvested and analyzed
for soluble collagen content excreted from cells
(Figure 4). Vehicle-treated cells exhibited virtually no
collagen production (denoted 1-fold). TGF-b1–treated cells
had nearly a 5-fold increase in collagen production relativemarkers. Actin cytoskeleton of vehicle-treated RL-65 cells showed intact
wth factor b1 (TGF) resulted in loss of actin ring and formation of visible
RAPA) treatments mimicked cytoskeletal rearrangements of transforming
tin ring; however, overall shape of the ring seemed to be elongated and ir-
osporine, mycophenolic acid, and sirolimus also resulted in loss of E-cad-
reas cells exposed to tacrolimus (TAC) and prednisone (PRED)maintained
ing growth factor b1 treatment greatly increased fibronectin deposition, as
ells expressed increased fibronectin compared with VEH while also main-
baseline levels of fibronectin expression.
ery c February 2011
FIGURE 4. Collagen production. Medium harvested from cell cultures
was analyzed for presence of soluble collagen and normalized to total pro-
tein from same cultures. Cells treated with vehicle (VEH) exhibited virtu-
ally no collagen secretion, which we scaled to 1. Cells treated with
transforming growth factor b1 (TGF) had nearly 5-fold increase in collagen
production relative to vehicle-treated cells. Cells treated with cyclosporine
(CSA) and sirolimus (RAPA) showed largest increases in collagen produc-
tion, both at similar levels to transforming growth factor b1–treated cells.
Cells treated with mycophenolic acid (MMF) and azathioprine (AZA) ex-
hibited 3- and 4-fold increases in collagen production, respectively. Cells
treated with tacrolimus (TAC) and prednisone (PRED) were comparable
to vehicle-treated cells. Asterisk indicates significant difference from
vehicle, P<.05.
Felton et al Cardiothoracic Transplantationto vehicle-treated cells. Cyclosporine-treated cells also had
a 5-fold increase in collagen production. The collagen
production increases in azathioprine-, mycophenolic
acid–, and sirolimus-treated cells ranged from 3- to 4-
fold. Tacrolimus- and prednisone-treated cells showed no
significant increase in soluble collagen production relative
to vehicle-treated cells.T
XTGF-b1 Production
With TGF-b1 stimulation as a positive control, enzyme-
linked immunosorbent assay–detected TGF-b1 was nearly
1.5-fold that of vehicle-treated cells (Figure 5, A). Pro-
longed exposure with cyclosporine resulted in the greatest
induction of TGF-b1 expression at just under a 1-fold in-
crease. Azathioprine- and mycophenolic acid–treated cells
both exhibited a 0.5-fold increase in TGF-b1 production.
Sirolimus showed nearly a 1-fold increase in TGF-b1 excre-
tion similar to that of cyclosporine. Notably, tacrolimus-
and prednisone-treated cells had no significant upregulation
of TGF-b1 and were comparable to vehicle-treated cells.Anti–TGF-b1 Rescue
Previously we demonstrated fibronectin expression with
exposure to TGF-b1 and certain immunosuppressive drugs
(Figure 2). In addition, coincubation with anti–TGF-b1 suc-
cessfully maintained expression of fibronectin at baseline
levels in the presence of immunosuppressive drugs
(Figure 5, B). Fibronectin was chosen because it is a mainThe Journal of Thoracic and Cacomponent of ECM, and we therefore considered it to be
the most clinically relevant marker. By immunoblot, we
compared levels of fibronectin after treatment with each
immunosuppressant and anti–TGF-b1 with TGF-b1 alone
as a positive control and with TGF-b1 in the presence of
anti–TGF-b1 as a negative control. Fibronectin expression
was preserved at baseline levels in the presence of all
immunosuppressive drugs when cells were cotreated with
anti–TGF-b1.
DISCUSSION
In this study we showed the capacity of bronchial epithe-
lial cells to undergo a partial EMT.We used the rat bronchial
epithelial cell line RL-65 to show that stimulation with
TGF-b1 and also treatment with certain immunosuppressive
agents increased expressions of the ECM proteins fibronec-
tin and collagen. We confirmed the loss of epithelial marker
AQP5 in the presence of each drug without, however, any
noticeable loss in overall ECAD expression. Wewere none-
theless able to show a marked loss of ECAD localized to the
cell membrane. Furthermore, we found that immunosup-
pressive agent–induced EMTwas associated with upregula-
tion of TGF-b1 expression and that the presence of anti–
TGF-b1 before administration of an immunosuppressive
drug prevented this upregulation of fibronectin expression.
Despite great improvements in patient selection, surgical
techniques, and postoperative care, the airway fibrosis with
luminal narrowing of OB remains the most important limit-
ing factor in long-term survival after lung transplant. The
pathology of OB is poorly understood, but the current per-
spective is that OB is the result of chronic injuries from the
host immune response, viral infections, and environmental
contaminants.3,4 In most instances, the airway epithelium is
the target of these insults.15 We propose that chronic insults
induce an improperly regulated wound healing response as-
sociated with increased TGF-b1 expression. TGF-b1, the
main cytokine responsible for triggering EMT, could induce
transition of airway epithelium to fibroblastlike cells, de-
positing ECM proteins and causing fibrous buildup within
the airway walls.
Clinical evidence for EMT has been provided previously
byWard and colleagues,16 who showed EMTmarkers in al-
lografts of stable lung transplant recipients. In addition,
Borthwick and colleagues8 previously showed the capacity
for EMT in human airway epithelial cells and a greater
prevalence of EMT markers in patients with OB relative
to stable recipients and control lung samples. Our data sup-
port these findings by demonstrating that another bronchial
epithelial cell line has the capacity to downregulate epithe-
lial markers in association with increased collagen, fibro-
nectin, and vimentin in response to TGF-b1 stimulation.
TGF-b1 is a known mediator for the induction of fibrosis
in many organs, including the lung.17 It is becoming in-
creasingly recognized that much of this TGF-b1–generatedrdiovascular Surgery c Volume 141, Number 2 527
FIGURE 5. Transforming growth factor b1 (TGF) production by bronchial epithelial cells and anti–transforming growth factor b1 rescue. A, Presence of
transforming growth factor b1 in culture medium samples was assayed by enzyme-linked immunosorbent assay. Transforming growth factor b1–positive
control showed 1.5-fold increase in present transforming growth factor b1. Treatments with cyclosporine (CSA) and sirolimus (RAPA) elicited approxi-
mately 1.0-fold increases in transforming growth factor b1 production relative to cells treated with vehicle (VEH), whereas azathioprine (AZA) and myco-
phenolic acid (MMF) treatments resulted in approximately 0.5-fold increase. Cells treated with tacrolimus (TAC) and prednisone (PRED) were comparable
to vehicle-treated cells. B, To demonstrate immunosuppressive-induced transforming growth factor b1 production as potential mechanism for immunosup-
pressive agent–induced epithelial–mesenchymal transition, we coincubated each immunosuppressive treatment with anti–transforming growth factor b1. As
negative control, cells were treated with 2.5-ng/mL transforming growth factor b1 and 5-ng/mL anti–transforming growth factor b1. Transforming growth
factor b1 alone served as positive control. Each immunosuppressive drug treatment coincubated with anti–transforming growth factor b1 resulted in
maintenance of baseline fibronectin levels. Asterisk indicates significant difference from vehicle, P<.05.
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Xfibrogenesis, repair, scar formation, and deposition of ECM
in tissues is mediated through EMT. In the lung, EMT has
been most thoroughly examined in alveolar type II cells, in-
cluding how their ability to transition into myofibroblasts
contributes to idiopathic pulmonary fibrosis.18 It is known
that TGF-b1 is upregulated in the lungs of patients with id-
iopathic pulmonary fibrosis.19 Similarly, investigators have
shown a prominent role for TGF-b1 in the pathogenesis of
both clinical and experimental OB. El-Gamel and associ-
ates9 found that increased TGF-b1 production both corre-
lated with and preceded histologic presentation of OB in
transplant recipients. Experimentally, Ramirez and co-
workers20 prevented the manifestation of OB in tracheal
transplant models by blocking TGF-b1–SMAD3 signaling,
showing that this cytokine signaling pathway is essential in
the development of OB.
Improvements in immunosuppression strategies have been
central to the long-term success of all solid organ transplants.
Historically, it was the discovery of the immunosuppressive
effects of cyclosporine that revolutionized the field of solid
organ transplantation. The primary limitation to the long
term use of cyclosporine has been irreversible renal toxicity,
which is characterized histologically by renal interstitial fi-
brosis.21 There is evidence that suggests that cyclosporine-528 The Journal of Thoracic and Cardiovascular Surginduced renal tubulointerstitial fibrosis is mediated by prox-
imal tubular epithelial cell EMT.11 Furthermore, others have
reported that the profibrotic effects of cyclosporine on
proximal tubular epithelial cells is associated with upregula-
tion of TGF-b1.22 These observations led us to consider
whether immunosuppressive agents could contribute to the
fibrotic airway remodeling seen in OB, and whether
disparities in clinically observed treatment outcomes were
related to the immunosuppressive agent–induced fibrosis.
Our data similarly demonstrate that cyclosporine can
trigger an EMT response in bronchial epithelial cells.
Cyclosporine upregulated expressions of fibronectin and
vimentin. In addition, collagen synthesis was increased in
the presence of cyclosporine. Meanwhile, expression of
the epithelial marker AQP5 was downregulated in the pres-
ence of cyclosporine. There was no difference in the overall
expression of the epithelial marker ECAD; however, immu-
nofluorescence demonstrated a distinct change in the cellu-
lar localization of ECAD, as well as actin cytoskeletal
rearrangement. The loss of ECAD at the membrane sug-
gests transition toward a motile phenotype, as seen in clas-
sic EMT; because the cells do not downregulate overall
ECAD expression, however, the cells may harbor a limited
capacity to undergo complete EMT. It is interesting to noteery c February 2011
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Xthat, unlike cyclosporine, tacrolimus did not trigger an EMT
response. This finding correlates with clinical evidence that
patients treated with tacrolimus have a significantly lower
incidence of OB than those treated with cyclosporine.23
Similarly, others have shown that in tissue culture cyclo-
sporine but not tacrolimus induces upregulation of secretion
of TGF-b1 from human small airway epithelial cells.24
The agents azathioprine, mycophenolic acid, and siroli-
mus demonstrated similar responses to cyclosporine.
From a clinical standpoint, the choice of purine synthesis
inhibitors also seems to be shifting away from azathioprine
and toward mycophenolic acid. With no differences in the
management of the stages of chronic rejection, mycophe-
nolic acid treatment of patients trended toward a small
improvement in graft loss relative to azathioprine.25 In
our study, we noticed similar effects of these drugs. Both
advanced EMT in bronchial epithelium; however, myco-
phenolic acid showed significantly less nuclear blebbing,
often a precursor to apoptosis caused by DNA damage,
than did azathioprine. Although not mechanistically related
to EMT, this decreased nuclear damage could be associated
with the improved outcomes seen with mycophenolic acid
relative to azathioprine. Furthermore, sirolimus has become
an attractive drug option because of its lack of nephrotoxi-
city. Severe pulmonary toxicity has been reported,26 how-
ever, which may correlate to the severe effect observed on
the lung epithelium morphology, EMT marker production,
and TGF-b1 and collagen production.
The exact mechanism of development of OB remains un-
certain, but the potential role of EMTmay lead to therapeutic
targets—specifically, TGF-b1’s downstream actors. The lung
is a highly susceptible organ, and general injuries to the
epithelium such as from physical trauma, infection, or pollut-
ants can result in triggered wound healing response and
increased TGF-b1.3,27 As our data demonstrate, certain
immunosuppressive drugs also increase TGF-b1 production
in bronchial epithelial cells. At this point we can only
speculate on the mechanism of immunosuppressive agent–
induced TGF-b1 production, but we suspect that it is part
of a general injury response to the toxic effects of the drugs.
In addition, we found that the EMT triggering effects
of immunosuppressive drugs were diminished in the
presence of anti–TGF-b1. It should be noted that chronic
injuries potentially triggering EMT are not limited to
immunosuppressive drug toxicity; however, management of
this toxicity could prevent unnecessary exacerbation of OB.
Limitations of this study include the use of an immortal-
ized nonhuman cell line. Further studies should examine
the capacity of primary human cells to undergo EMT in re-
sponse to immunosuppressive agents. In addition, although
animal models for OB lack rigor, the effects of certain im-
munosuppressive agents should be tested in an appropriate
in vivo model. Furthermore, our data revealed an interest-
ing discrepancy between EMT studies in bronchial epithe-The Journal of Thoracic and Calium and alveolar epithelium. Whereas studies on alveolar
cells resulted in classic EMT, including significant upregu-
lation of a-smooth muscle actin,28 we did not detect any
increase in a-smooth muscle actin in our study (data not
shown). Furthermore, the relative increase in vimentin
was small relative to increases seen in studies done with
alveolar epithelial cells. This may suggest that bronchial
epithelium, or any nonprogenitor epithelial cell in the
same organ, may have a limited capacity relative to type
II alveolar cells to undergo what we define as EMT.
Whereas EMT is typically thought to result in the emer-
gence of myofibroblasts, we could be seeing a partial
EMT phenotype capable of ECM protein production but
limited in its motile and contractile facilities, perhaps ex-
plaining the distinct localization of fibrosis seen in OB as
opposed to the distributed fibrotic foci seen in idiopathic
pulmonary fibrosis. Unfortunately, this limitation was out-
side of the scope of this investigation, but it should be
studied more closely in the future. We believe that this par-
tial EMT response is directly relevant to the distinct fi-
brotic presentation of OB.
In conclusion, our study provides further evidence for the
capacity of bronchial epithelium to undergo TGF-b1–medi-
ated EMT. Furthermore, we have demonstrated that cyclo-
sporine and other immunosuppressive agents can trigger
an EMT response that appears to be mediated at least in
part by TGF-b1. This study found that TGF-b1 and the
commonly used immunosuppressive drugs cyclosporine,
mycophenolic acid, and sirolimus caused upregulations of
the mesenchymal markers fibronectin and vimentin and
also increased collagen production. Downregulation of the
epithelial marker AQP5 was seen with these drugs, along
with altered intracellular ECAD localization. These find-
ings may have direct implications regarding the mechanism
of airway remodeling and fibrosis seen in OB after lung
transplant, as well as regarding selection of immunosup-
pressive agents. Understanding the mechanisms of immu-
nosuppressive agent–induced bronchial epithelial EMT
may lead to novel protective and therapeutic strategies in
the management of OB after lung transplant.
We would like to thank the St. Joseph’s Foundation (Phoenix,
Ariz) for their generous support of this study and their support
of the Heart and Lung Research Initiative.
References
1. Berry GJ, Brunt EM, Chamberlain D, Hruban RH, Sibley RK, Stewart S, et al. A
working formulation for the standardization of nomenclature in the diagnosis of
heart and lung rejection: Lung Rejection Study Group. The International Society
for Heart Transplantation. J Heart Transplant. 1990;9:593-601.
2. Boehler A, Kesten S, Weder W, Speich R. Bronchiolitis obliterans after lung
transplantation: a review. Chest. 1998;114:1411-26.
3. Halloran PF, Homik J, Goes N, Lui SL, Urmson J, Ramassar V, et al. The ‘‘injury
response’’: a concept linking nonspecific injury, acute rejection, and long-term
transplant outcomes. Transplant Proc. 1997;29:79-81.
4. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors
influence chronic allograft rejection. Transplantation. 1995;59:313-8.rdiovascular Surgery c Volume 141, Number 2 529
Cardiothoracic Transplantation Felton et al
T
X5. Epperly MW, Guo H, Gretton JE, Greenberger JS. Bone marrow origin of myo-
fibroblasts in irradiation pulmonary fibrosis. Am J Respir Cell Mol Biol. 2003;29:
213-24.
6. Schurch W, Seemayer TA, Gabbiani G. The myofibroblast: a quarter century
after its discovery. Am J Surg Pathol. 1998;22:141-7.
7. Willis BC, Borok Z. TGF-b–induced EMT: mechanisms and implications
for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:
L525-34.
8. Borthwick LA, Parker SM, Brougham KA, Johnson GE, Gorowiec MR, Ward C,
et al. Epithelial to mesenchymal transition (EMT) and airway remodelling after
human lung transplantation. Thorax. 2009;64:770-7.
9. El-Gamel A, Sim E, Hasleton P, Hutchinson J, Yonan N, Egan J, et al. Transform-
ing growth factor b (TGF-b) and obliterative bronchiolitis following pulmonary
transplantation. J Heart Lung Transplant. 1999;18:828-37.
10. Hodge S, Holmes M, Banerjee B, Musk M, Kicic A, Waterer G, et al. Posttrans-
plant bronchiolitis obliterans syndrome is associated with bronchial epithelial to
mesenchymal transition. Am J Transplant. 2009;9:727-33.
11. Slattery C, Campbell E, McMorrow T, Ryan MP. Cyclosporine A–induced renal
fibrosis: a role for epithelial-mesenchymal transition. Am J Pathol. 2005;167:
395-407.
12. Roberts PE, Phillips DM, Mather JP. A novel epithelial cell from neonatal rat
lung: isolation and differentiated phenotype. Am J Physiol. 1990;259(6 Pt 1):
L415-25.
13. Monchaud C, Marquet P. Pharmacokinetic optimization of immunosuppressive
therapy in thoracic transplantation: part II.Clin Pharmacokinet. 2009;48:489-516.
14. Masuda S, Inui K. An up-date review on individualized dosage adjustment of cal-
cineurin inhibitors in organ transplant patients. Pharmacol Ther. 2006;112:
184-98.
15. Fernandez FG, Jaramillo A, Chen C, Liu DZ, Tung T, Patterson GA, et al. Airway
epithelium is the primary target of allograft rejection in murine obliterative air-
way disease. Am J Transplant. 2004;4:319-25.
16. Ward C, Forrest IA, Murphy DM, Johnson GE, Robertson H, Cawston TE, et al.
Phenotype of airway epithelial cells suggests epithelial to mesenchymal
cell transition in clinically stable lung transplant recipients. Thorax. 2005;60:
865-71.530 The Journal of Thoracic and Cardiovascular Surg17. Sime PJ, O’Reilly KM. Fibrosis of the lung and other tissues: new concepts in
pathogenesis and treatment. Clin Immunol. 2001;99:308-19.
18. Willis BC, duBois RM, Borok Z. Epithelial origin of myofibroblasts during fibro-
sis in the lung. Proc Am Thorac Soc. 2006;3:377-82.
19. Bergeron A, Soler P, Kambouchner M, Loiseau P, Milleron B, Valeyre D, et al.
Cytokine profiles in idiopathic pulmonary fibrosis suggest an important role
for TGF-b and IL-10. Eur Respir J. 2003;22:69-76.
20. Ramirez AM, Shen Z, Ritzenthaler JD, Roman J. Myofibroblast transdifferentia-
tion in obliterative bronchiolitis: TGF-b signaling through smad3-dependent and
-independent pathways. Am J Transplant. 2006;6:2080-8.
21. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated
chronic nephropathy. N Engl J Med. 1984;311:699-705.
22. Johnson DW, Saunders HJ, Johnson FJ, Huq SO, Field MJ, Pollock CA. Fibro-
genic effects of cyclosporin A on the tubulointerstitium: role of cytokines and
growth factors. Exp Nephrol. 1999;7:470-8.
23. Keenan RJ, Konishi H, Kawai A, Paradis IL, Nunley DR, Iacono AT, et al. Clin-
ical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac
Surg. 1995;60:580-5.
24. Zhang JG, Walmsley MW, Moy JV, Cunningham AC, Talbot D, Dark JH, et al.
Differential effects of cyclosporin A and tacrolimus on the production of
TGF-b: implications for the development of obliterative bronchiolitis after
lung transplantation. Transpl Int. 1998;11(Suppl. 1):S325-7.
25. Speich R, Schneider S, Hofer M, Irani S, Vogt P, Weder W, et al. Mycophenolate
mofetil reduces alveolar inflammation, acute rejection and graft loss due to bron-
chiolitis obliterans syndrome after lung transplantation. Pulm Pharmacol Ther.
2010;23(5):445-9.
26. Gupte GL, Mahadevan S, Clarke JR, Alton H, Beath SV. Sirolimus-related pul-
monary toxicity mimicking ‘asthma like’ symptoms. World J Gastroenterol.
2007;13:5151-3.
27. Crosby LM, Waters CM. Epithelial repair mechanisms in the lung. Am J Physiol
Lung Cell Mol Physiol. 2010;298:L715-31.
28. Willis BC, Liebler JM, Luby-Phelps K, Nicholson AG, Crandall ED, du
Bois RM, et al. Induction of epithelial-mesenchymal transition in alveolar epithe-
lial cells by transforming growth factor-beta1: potential role in idiopathic pulmo-
nary fibrosis. Am J Pathol. 2005;166:1321-32.ery c February 2011
